After a conference lacking the wow factor, biotech winners and losers emerge.
ApexOnco Front Page
Recent articles
16 September 2024
Despite seeing dose-limiting toxicities, the group is going higher with its KRAS G12D project.
23 August 2024
Belrestotug’s lung cancer trial features among the ESMO late-breakers, as do Immutep, Scorpion and others.
23 August 2024
Second time lucky for Zynyz, Amgen’s PRMT5 comeback, and other possible surprises.
22 August 2024
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
21 August 2024
After several disappointments Bristol at last turns its Lag3/PD-1 combo to first-line lung cancer.
21 August 2024
Meanwhile, recent updates hint at more issues in the group’s pipeline of bispecific MAbs.
21 August 2024
Dizal and Daiichi have set the bar, but a lack of other interest in ITK inhibition could ring alarm bells.
Recent Quick take
- 11 July 2024
- 10 July 2024
- 9 July 2024
- 9 July 2024
- 8 July 2024
- 2 July 2024
- 1 July 2024
- 27 June 2024
- 25 June 2024
- 25 June 2024